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In autosomal dominant polycystic kidney disease (ADPKD),
abnormal proliferation of tubular cells drives cyst
development and growth. Sirolimus, an inhibitor of the
protein kinase mammalian target of rapamycin (mTOR) and a
potent anti-proliferative agent, decreases cyst growth in
several genetically distinct rodent models of polycystic
kidney disease (PKD). We determined here the effect of
sirolimus on renal cyst growth in Pkd2WS25/ mice; an
ortholog of human ADPKD involving mutation of the Pkd2
gene. In Pkd2WS25/ mice treated with sirolimus, both the
two kidney/total body weight (2K/TBW) ratio and the cyst
volume density (CVD) were significantly decreased by over
half compared with untreated mice suffering with PKD.
However, there was no effect on the increased blood urea
nitrogen (BUN) levels as an index of kidney function. There
are two distinct complexes containing mTOR depending on
its binding partners: mTORC1 and mTORC2. Western blot
analysis of whole kidney lysates and immunohistochemistry
of the cysts found that phospho-S6 ribosomal protein, a
marker of mTORC1 activity, was increased in Pkd2WS25/
mice and its phosphorylation was decreased by sirolimus
treatment. Phospho-Akt at serine 473, a marker associated
with mTORC2 activity, was not different between Pkd2WS25/
mice and normal littermate controls. Hence, our study found
that inhibition of mTORC1 by sirolimus correlated with
decreased renal cyst growth in this model of human ADPKD
but had no effect on the decline in renal function.
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We have previously shown in the Han:SPRD rat model of
polycystic kidney disease (PKD) that sirolimus treatment
decreases proliferation in cystic and non-cystic tubules,
markedly inhibits renal enlargement and cystogenesis and
prevents the loss of kidney function.1 Subsequently two other
studies have shown that mammalian target of rapamycin
(mTOR) inhibition with sirolimus2 or everolimus3 reduces
cyst formation and renal failure in the Han:SPRD rat. It has
also recently been shown that sirolimus decreases cyst
formation and renal failure in the orpk-rescue mouse
(defective cilia protein polaris) and the bpk mouse (over-
expressing myelin and lymphocyte protein) models of PKD.4
Autosomal dominant polycystic kidney disease (ADPKD) in
humans is caused by a mutation in the Pkd1 or Pkd2 gene.
The Han:SPRD rat, orpk, and bpk mouse do not have
primary abnormalities of the Pkd1 or Pkd2 genes as the cause
of the PKD. In this study, we tested the hypothesis that
sirolimus therapy would decrease PKD caused by a mutation
in the Pkd2 gene, in the Pkd2WS25/ mouse model. These
mice were engineered to have one of the Pkd2 alleles knocked
out and the other Pkd2 allele capable of undergoing high
rates of recombination with one of the recombination
products resulting in the loss of a functional gene. This
study in Pkd2WS25/ mice is important as not all therapies
that ameliorate murine cystic disease in diverse models
may be effective in disease caused by Pkd gene mutations
and the Pkd2WS25/ mice model closely resembles human
ADPKD.
The mTOR exists in association with two different
complexes, mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2). The mTORC1 is a complex of mTOR
and Raptor (regulatory associated protein of mTOR) whereas
mTORC2 is a complex of mTOR and Rictor (sirolimus-
independent companion of mTOR). The mTORC1 complex
regulates cell growth (size), proliferation, apoptosis, and
autophagy. Activation of mTORC1 has been shown in PKD
in rodents3–5 and in humans.6 The effect of PKD and
sirolimus on mTORC2 is not known. The mTORC2 increases
proliferation, inhibits apoptosis, regulates the actin
cytoskeleton, and can phosphorylate Akt at serine 473.7 As
proliferation and apoptosis8,9 cytoskeleton abnormalities10,11
or ig ina l a r t i c l e http://www.kidney-international.org
& 2010 International Society of Nephrology
Received 8 January 2010; revised 9 April 2010; accepted 11 May 2010;
published online 4 August 2010
Correspondence: Charles L. Edelstein, Division of Renal Diseases and
Hypertension, University of Colorado at Denver and the Health Sciences
Center, Box C281, 12700 East, 19th Ave, Aurora, CO 80262, USA.
E-mail: Charles.edelstein@ucdenver.edu
754 Kidney International (2010) 78, 754–761
and activation of Akt3 are features of PKD, the degree of
mTORC2 activation was determined.
In this study, we tested the hypotheses that there would be
increased mTORC1 and mTORC2 activation in Pkd2WS25/
mouse kidneys and that the mTORC1 inhibitor, sirolimus
would decrease PKD in Pkd2WS25/ mice.
RESULTS
Effect of sirolimus on body weight, kidney weight,
2K/TBW, CVD, and BUN
Sirolimus had no effect on the body weight (Table 1). This is
in contrast to previous reports showing that short-term
(5 week) 0.2 mg/kg/d sirolimus treatment in Han:SPRD rats
and wild-type male rats resulted in a 22% loss of body
weight.1 In this study, mice received a higher dose of
sirolimus (that is, 0.5 mg/kg/d) for a longer period of time
(that is, 8–12 weeks) but did not have weight loss.
Representative kidney sections of vehicle-treated
Pkd2WS25/ mice and sirolimus-treated Pkd2WS25/
mice, stained with hematoxylin-eosin, at the same magnifica-
tion are shown in Figure 1a and b. These representative
sections show that the percentage of the kidney that is
occupied by cysts is markedly reduced in the kidney obtained
from the sirolimus-treated Pkd2WS25/ mice.
The two kidney/total body weight ratio (2K/TBW), which
corrects for differences in body weight, was nearly double in
Pkd2WS25/ mice compared with vehicle-treated þ /þ
mice. Sirolimus resulted in a 61% decrease in 2K/TBW
(Table 1).
The increase in kidney weights in the Pkd2WS25/ mice
was directly paralleled by increases in the measured cyst
volume density (CVD) in the kidneys. Mean CVD percentage
was 39% in Pkd2WS25/ mice treated with vehicle and 20%
in Pkd2WS25/ mice treated with sirolimus. Sirolimus
resulted in a 51% decrease in CVD (Table 1).
The blood urea nitrogen (BUN) level was increased in
vehicle-treated Pkd2WS25/ mice and sirolimus-treated
Pkd2WS25/ mice compared with vehicle-treated þ /þ
mice and sirolimus-treated þ /þ mice. BUN concentration
was not different between vehicle-treated Pkd2WS25/ mice
and sirolimus-treated Pkd2WS25/ mice (Table 1).
Female Pkd2WS25/ mice have less severe PKD than that
that in males.12 Only two of the ten Pkd2WS25/ vehicle and
two of the ten Pkd2WS25/sirolimus-treated mice were
female. The two female Pkd2WS25/ mice treated with
sirolimus had a decrease in 2K/TBW (%) and CVD compared
with female littermate controls.
In the Pkd2WS25/ model, liver cyst formation increases
significantly after 16 weeks of age.12 This study ended at 16
weeks of age. At the end of the study, liver weight was
identical (1.6 g) in Pkd2Ws25/ treated with vehicle and
Pkd2Ws25/ treated with sirolimus.
Renal fibrosis
To evaluate renal fibrosis, quantitation of collagen deposition
by Masson’s trichrome staining was carried out. As shown in
Figure 2, sirolimus reduced collagen staining. The renal
failure in PKD has been linked to fibrosis. However, despite
the reduction in collagen staining by sirolimus, there was no
effect on kidney function by sirolimus.
Apotosis and caspase-3
The number of terminal deoxynucleotidyltransferase (TdT)-
mediated dUTP nick-end labeling (TUNEL)-positive apo-
ptotic cells per cyst was 0.15±0.06 in Pkd2WS25/ mice
treated with the vehicle and 0.26±0.09 in Pkd2WS25/ mice
treated with sirolimus (P¼ not significant vs vehicle-treated,
N¼ 4) (Figure 3). Representative pictures of TUNEL staining
are shown in Figure 3.
Caspase-3 is the major mediator of apoptosis. In support
of the data that there is no significant difference in apoptosis
with sirolimus treatment, caspase-3 activity was not
Table 1 | Effects of sirolimus in Pkd2WS25/ mice
+/+ vehicle (n=24) +/+ sirolimus (n=8)
Pkd2WS25/
vehicle (N=10)
Pkd2WS25/
sirolimus (N=10)
Body weight (g) 22.8±3.1 23.4±0.7 27.4±1 27.6±1
Kidney weight (g) 0.31±0.01 0.27±0.02 0.60±0.11* 0.44±0.04**
2K/TBW (%) 1.24±0.02 1.15±0.05 2.20±0.4* 1.63±0.1**
CVD (%) 0.5±0.2 0.5±0.2 38.8 ±3.7w 20.4±5.1ww
BUN (mg/dl) 16.7±0.9 17.5±0.9 33.8±4.2* 29.2±1.5z
Abbreviations: BUN, blood urea nitrogen; CVD, cystic volume density; NS, not significant; 2K/TBW, two kidney/total body weight.
*Po0.01 vs +/+ vehicle and +/+ sirolimus, **Po0.05 vs Pkd2WS25/ vehicle, NS vs +/+ vehicle and +/+ sirolimus. wPo0.001 +/+ vehicle and +/+ sirolimus, wwPo0.01 vs
Pkd2WS25/ vehicle, zNS vs Pkd2WS25/ vehicle. The P-value for the interaction between sirolimus and genotype was NS for kidney weight, NS for 2K/TBW (%), 0.009 for
CVD (%) and NS for BUN.
Figure 1 | Effects of sirolimus on polycystic kidney disease
(PKD) in Pkd2WS25/ mice. Representative sections at the
same magnification, stained with hematoxylin and eosin, show
more renal cysts in (a) vehicle-treated compared with
(b) sirolimus-treated Pkd2WS25/ mice.
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significantly affected by sirolimus. Caspase-3 activity (nmol/
min/mg) was 5.4±2.3 in Pkd2WS25/ mice treated with the
vehicle and 2.9±1.7 in Pkd2WS25/ mice treated with
sirolimus (P¼not significant vs vehicle-treated, N¼ 5).
mTORC1 activity
Activation of mTORC1, but not mTORC2, results in the
phosphorylation of S6 ribosomal protein. On immunoblot-
ting there was an increase in phospho-S6 ribosomal protein
in vehicle-treated Pkd2WS25/ mouse kidneys compared
with kidneys from normal littermate controls (þ /þ )
(Figure 4). The increase in phospho-S6 ribosomal protein
in Pkd2WS25/ kidneys was inhibited by sirolimus (Fig-
ure 4). Total S6 ribosomal protein, used as a control, was not
significantly different in vehicle-treated controls (þ /þ ),
vehicle-treated Pkd2WS25/, vehicle-treated Pkd2WS25/,
and sirolimus-treated Pkd2WS25/ kidneys (Figure 4).
To identify the localization of phospho-S6 ribosomal
protein, immunohistochemical staining was performed. On
immunohistochemical staining, there was increased phos-
pho-S6 ribosomal protein in both noncystic and cystic
tubules of Pkd2WS25/ mice. The increase in phospho-S6
ribosomal protein was decreased by sirolimus. Representative
pictures of phospho-S6 ribosomal protein staining are shown
in Figure 5.
mTORC2 activity
On immunoblotting of whole kidney lysates, Rictor protein
was not significantly different between normal littermate
controls (þ /þ ) and Pkd2WS25/ mice kidneys (Figure 6a).
Interestingly, sirolimus treatment of Pkd2WS25/ resulted in
a significant decrease in the abundance of Rictor (Figure 6b).
Phospho-AKT (serine 473) is directly phosphorylated by
mTORC2 and phospho-AKT is a marker of mTORC2
activation.13–15 Phospho-AKT (serine 473) was not different
in whole kidney lysates between normal littermate controls
and Pkd2WS25/ kidneys (Figure 7a). Furthermore,
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Figure 2 |Representative Masson’s Trichrome staining. There was no collagen staining (blue) in control mice (þ /þ ) (a). There was
extensive collagen staining (blue) (arrows) in Pkd2WS25/ mice (b) that was decreased by sirolimus (c).
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Figure 3 |Representative TUNEL-staining. (a) Quantitation of
apoptotic cells per tubule. TUNEL-positive tubular cells (dark
brown staining, arrows) are shown in Pkd2WS25/ mice treated
with vehicle (Veh) (b) and Pkd2WS25/ mice treated with
sirolimus (Sir) (c).
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Figure 4 |Phospho-S6 immunoblotting. There was an increase
in phospho-S6 protein in cystic and noncystic tubules between
normal littermate control (þ /þ ) and Pkd2WS25/ (WS) mice.
The increase in phospho-S6 was significantly decreased by
sirolimus in normal littermate control (þ /þ Sir) and Pkd2WS25/
(WSþ Sir). Total S6 used as a control was not different between
the groups. Densitometry for phospho-S6 reflects five separate
experiments. *Po0.05 vs þ þ , **Po0.05 vs þ þ , **Po0.05 vs
WSþ Sir.
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sirolimus had no inhibitory effect on levels of phospho-AKT
(serine 473) (Figure 7b).
DISCUSSION
Two mutations have been induced in the mouse homolog
Pkd2 gene: an unstable allele (WS25; also known as
Pkd2WS25/ mice) that can undergo homologous recombi-
nation-based somatic rearrangement to form a null allele;
and a true null mutation (WS183; also known as Pkd2/
mice).16 Adult Pkd2þ / mice have intermediate survival in
the absence of cystic disease or renal failure, providing the
first indication of a deleterious effect of haploinsufficiency of
Pkd2 on long-term survival. As in human ADPKD,
formation of kidney cysts in adult Pkd2WS25/ mice is
associated with renal failure and early death. The vasopressin
V2 receptor antagonist OPC31260 decreases renal CVD and
BUN in Pkd2WS25/ mice.17 Treatment of Pkd2WS25/
mice between 4 and 8 months of age with the VEGFR
inhibitor, SU-5416, markedly reduced liver weight and CVD
of the liver.18 These adult Pkd2WS25/ mice were used in
this study. Study of mice with targeted mutations of the PKD
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Figure 5 |Phospho-S6 immunohistochemistry. Left panel
100 magnification. Right panel 400 magnification. Phospho-
S6 staining is brown. There was less staining in sirolimus-treated
normal littermate controls compared with vehicle-treated normal
littermate controls. There was less staining in Pkd2DWS25/
sirolimus-treated compared with Pkd2WS25/ vehicle treated.
There was staining in normal tubules in vehicle-treated normal
littermate controls and to a lesser extent in sirolimus-treated
normal littermate controls. There was staining in noncystic
tubules and small cysts in Pkd2WS25/ vehicle treated and to a
lesser extent in Pkd2WS25/ sirolimus-treated. There was no
staining in glomeruli (arrows). Asterisk¼ cysts.
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Figure 6 |Rictor immunoblot. Rictor is increased in Pkd2WS25/
kidneys (WS) compared with normal littermate controls (þ þ )
(a). Rictor is decreased in Pkd2WS25/ kidneys treated with
sirolimus (WS Sir) compared with Pkd2WS25/ kidneys treated
with vehicle (WS Veh) (b). Actin used as a loading control was
equal in all the groups. Densitometry for Rictor reflects six
separate experiments. NS, not significant, **Po0.05 vs WS Veh.
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Figure 7 |Phospho-Akt (serine 473) immunoblot. Phospho-Akt
(serine 473) induces proliferation and inhibits apoptosis. Phospho-
Akt (serine 473) is directly phosphorylated by the mTOR–Rictor or
mTORC2 complex and is a marker of mTORC2 activity. Phospho-
Akt (serine 473) was not increased in Pkd2WS25/ kidneys (WS)
compared with littermate controls (þ þ ) (a). Phospho-Akt (serine
473) was not different between Pkd2WS25/ kidneys treated with
vehicle (WS Veh) compared with Pkd2WS25/ kidneys treated
with sirolimus (WS Sir) (b). Total Akt used as a control was not
different between the groups. Densitometry for Phospho-Akt
(serine 473) reflects six separate experiments. NS, not significant.
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gene have advanced our understanding of ADPKD as these
mouse models recapitulate the complex human ADPKD
phenotype.19
Human and experimental data provide strong evidence
that abnormal proliferation in tubular epithelial cells has a
crucial role in cyst development and/or growth in PKD.20
Genetic manipulations that induce the proliferation of
tubular epithelial cells in mice cause cysts to form in the
kidney.21,22 The therapeutic effect of sirolimus in PKD is
related to its anti-proliferative effect. Although the prolifera-
tion index is consistently highest in cystic tubular epithelium,
non-cystic tubules from mice suffering with PKD23 and
Han:SPRD rats1,24 have higher proliferation rates than
tubules from age-matched controls. These studies suggest
that tubular cell proliferation precedes cyst formation in the
Han:SPRD rat.24 In Pkd2WS25/ mice, increased cell
proliferation is an early event preceding cyst formation.25
In this study non cystic tubules from Pkd2WS25/ mice had
higher expression of phospho-S6 protein than non cystic
tubules from wild-type mice (Figure 4) suggesting that
activation of the mTORC1 signaling pathway is an early event
preceding cyst formation. In this study, sirolimus therapy was
started at 4–8 weeks of age, a time when there is already
significant proliferation and kidney cyst formation in
Pkd2WS25/ mice.16,25 Thus, it is likely that initiation of
therapy earlier would have had a better therapeutic effect. On
the other hand sirolimus therapy initiated after significant
proliferation and cyst formation, as in this study, still had a
therapeutic effect. Thus, this study has implications for the
treatment of patients, which in many cases will be initiated
after significant cyst formation.
The Pkd2WS25/ mice had a 2K/TBW ratio that was
nearly double that of normal littermate control mice. The
Pkd2WS25/ mice had chronic kidney disease as indicated
by a BUN concentration that was double that of normal
littermate control mice. Sirolimus significantly decreased
kidney and cyst size but had no effect on the chronic kidney
disease as assessed by the BUN. Although an inverse
relationship between increasing cyst volume and decreasing
kidney function is known,26 it is shown that the 51% decrease
in CVD caused by sirolimus was not enough to affect renal
function in Pkd2WS25/ mice.
Therapeutic blood levels of sirolimus in humans are
5–15 ng/ml. The mean trough sirolimus levels in ‘þ þ ’ and
‘ws25’ mice was above therapeutic levels. The high blood
levels raise the possibility that sirolimus nephrotoxicity may
have contributed to the lack of an effect of sirolimus on BUN.
However, sirolimus has minimal functional and histopatho-
logical effects in normal rat and mouse kidney. In
Sprague–Dawley rats, sirolimus (10 mg/kg/d), a dose three
times higher than its effective immunosuppressive dose, had
no functional or histological effects on the kidney.27 In mice,
sirolimus (up to 100 mg/kg), a dose 50 times higher than its
therapeutic dose, reduced body weight after 7 days but had
minimal effect on kidney function and histology.28 Thus, as
opposed to cyclosporin, we do not think that there was
nephrotoxicity due to sirolimus. In addition, unlike
Han:SPRD rats treated with sirolimus (0.2 mg/kg/d) for
5 weeks1 or 1 year29 that 22% loss in body weight,
the Pkd2WS25/ mice or normal littermate control mice
treated with 0.5 mg/kg/d did not experience weight loss
suggesting that weight loss was not a side effect of sirolimus
therapy in mice.
Next we sought to determine why sirolimus did not have a
better therapeutic effect. It is possible that a higher dose of
sirolimus or earlier initiation of therapy may have had a
better therapeutic effect. As kidney size and CVD were not
normalized by sirolimus, we investigated the mTORC2
pathway that is known to be proliferative through phosphor-
ylation of phospho-Akt (serine 473).7,13 Rictor and phospho-
Akt (serine 473), the functional readout of the mTOR–Rictor
mTORC2 complex activity, were not different between
normal littermate control and Pkd2WS25/ kidneys at 16
weeks of age. However, Rictor in whole kidney lysates was
decreased by sirolimus in Pkd2WS25/ mice. A possible
reason for the difference between Rictor and phospho-Akt
(serine 473) expression is that Rictor expression in whole
kidney lysates does not accurately reflect mTORC2 assembly
or the effect of sirolimus on mTORC2 assembly.14,15 Rather,
the Rictor-mTOR complex on immunopreciptates of cells,
not whole cell lysates, reflects mTORC2 assembly and Akt
(serine 473) activity.14,15 Long term or high-dose sirolimus
therapy14,30 is able to inhibit mTORC2 assembly, as seen on
immunoprecipitation, and resultant phosphorylation of Akt
(serine 473).
In this study, we show activation of mTORC1 (increased
ribosomal S6 protein), but not mTORC2, in PKD caused by a
mutation of the Pkd2 gene. Having shown that there is
increased mTORC1 signaling in Pkd2WS25/ kidneys and
that sirolimus significantly decreases kidney size and CVD in
Pkd2WS25/ mice, we speculated on how the mutation in
the Pkd2 gene as seen in Pkd2WS25/ mice, may affect
mTORC1 signaling. PC-2, the protein product of the Pkd2
gene binds to polycystin-1 (PC-1), a large transmembrane
receptor.31 PC-1 and PC-2 are proposed to constitute a flow-
sensitive ion channel complex in the primary cilium. It has
recently been discovered that the PC-1/PC-2 ratio regulates
pressure sensing.32 The PC-1 and PC-2 proteins associate in a
complex to prevent cyst formation.7 For example, PC-1
induces the formation of a complex with tuberin and the ser/
thr kinase of mTOR resulting in inhibition of mTORC1
activity.5 Most recently, direct evidence that PC-1 inhibits
mTORC1 in a tuberin-dependent manner by regulation of
ERK-dependent phosphorylation was shown.33 Thus, the PC-
1/TSC-1-TSC-2 complex inhibits mTORC1.34 In contrast, the
TSC-1—TSC-2 complex activates mTORC2 in a manner that
is independent of the effect of the TSC-1–TSC-2 complex on
mTORC1.34 Thus, if a mutation of PC-2 in the PC-2–PC-1
complex was acting through TSC-1/TSC-2, there would be an
increase in mTORC1 and inhibition of mTORC2 in
Pkd2WS25/ mice. The fact that mTORC2 was not increased
in Pkd2WS25/ mice may be because of the inhibitory effect
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of a mutation in the PC-2–PC-1 complex acting through
TSC-1/TSC-2 to inhibit mTORC2.
A recent study by Weimbs et al.35 shows that sirolimus
ameliorates PKD in mice with a conditional inactivation of
the Pkd1 gene. This study shows a similar effect of sirolimus
in mice with a mutation in the Pkd2 gene. However, there are
important differences between this study and the study of
Weimbs et al. In this study, the sirolimus dose was 0.5 mg/kg
intraperitoneal compared with 5 mg/kg intraperitoneal in the
Weimbs study. In view of the sirolimus trough levels of
20–22 ng/ml with 0.5 mg/kg, it is unlikely that a higher dose
of sirolimus would have had a better effect on the PKD.
Despite a decrease in fibrosis because of sirolimus in both
studies, in the Weimbs study, sirolimus normalized the BUN
in PKD mice whereas in this study sirolimus had no effect on
BUN. In the Weimbs study there was a marked increase in
Akt (serine 473) that was decreased by sirolimus, whereas in
this study there was no increase in Akt (serine 473). In the
Weimbs study, sirolimus increased apoptosis of cyst lining
epithelial cells whereas in this study sirolimus had no
significant effect on apoptosis and caspase-3 activity. The
lack of effect of sirolimus on apoptosis may be related to the
data that sirolimus had no effect on mTORC2, which is
known to modulate apoptosis.
In summary, we show for the first time, increased
mTORC1 signaling and a therapeutic effect of sirolimus in
a model of PKD due to a mutation in the Pkd2 gene. In
addition we show that phospho-Akt (serine 473), a marker of
mTORC2 activation, is not different in the kidney in
Pkd2WS25/ and wild-type control mice at 16 weeks of
age. The relevance of these studies to clinical ADPKD is
substantial and the results should provide leads to planning
clinical studies in PKD. This is particularly true because of
the current availability of mTOR antagonists for example,
sirolimus and its analogs and their proven in vivo beneficial
effect as immunosuppressive drugs and cancer treatments. In
addition, the use of agents that inhibit both mTORC1 and
mTORC2 may be an attractive future therapy.
MATERIALS AND METHODS
Animals
The study was conducted in Pkd2WS25/ mice and normal
littermate control (þ /þ ) mice. The Pkd2WS25/ mouse develops
clinically detectable PKD by 12 weeks of age as evidenced by a CVD of
more than 50% of the kidney and renal failure compared with þ /þ
control mice.16,17,36 A colony of Pkd2WS25/ mice was established in
our animal care facility from a litter that was obtained from Stefan
Somlo at Yale University. The study protocol was approved by the
University of Colorado Denver Animal Care and Use Committee. Mice
had free access to tap water and standard rat chow.
Genotyping
C57BL/6 Pkd2þ / and C57BL/6 Pkd2WS25/þ mice were used as
breeding pairs to generate Pkd2WS25/ mice for the study. Mice
were genotyped by Southern blotting.16,18 Briefly, DNA was isolated
from tail snips (Gentra Systems, Minneapolis, MN, USA) and
digested overnight with PstI restriction enzyme (Promega, Madison,
WI, USA). The cut DNA was run on a 0.7% agarose gel and
transferred onto nylon membranes overnight. A DNA probe specific
to the recombinant region was labeled with 32P by random priming
(Decaprime II, Ambion, Austin, TX, USA). The probes were incubated
with the blots overnight. Labeled blots were washed and developed by
autoradiography. The kdS25/ mice closely model the human
condition by having one copy of Pkd2 knocked out and having a
second, recombinant-sensitive allele (that is, WS25) that undergoes
high rates of recombination to yield knockouts of the second copy of
the gene in somatic cells during the lifespan of the animals.
Experimental protocol
Litters from Pkd2þ / mice crossed with Pkd2WS25/þ mice were
weaned at 3 weeks of age and then genotyped—a process that can
take up to 2 weeks. Sirolimus was obtained from LC Laboratories,
Woburn, MA, USA and a 1 mg/ml stock solution in 100% ethanol
was kept at 201C. Mice were treated with sirolimus 0.5 mg/kg/d
intraperitoneally or vehicle (10% ethanol in normal saline) from
4–16 weeks of age. This interval of treatment and the use of both
male and female mice is selected on the basis of previous studies.16,17
In four Pkd2WS25/ mice in the vehicle control group and four
Pkd2WS25/ mice in the sirolimus group, treatment was started at
6–8 weeks of age because of a delay in genotyping. Despite the delay
in initiation of treatment all four mice had a decrease in 2K/TBW
(%) and CVD compared with controls. Animals that were
genotyped after 8 weeks of age were excluded from the study. This
dose and route of administration of sirolimus is effective in C57BL6
mice with heart allograft rejection,37 cardiac hypertrophy,38 and
regenerating liver.39
At the end of the 16th week of age, mice were anesthetized by
intraperitoneal injection of pentobarbital sodium (50 mg/kg body
weight) and kidneys were removed and weighed. The left kidney was
fixed in 4% paraformaldehyde in phosphate-buffered saline for
120 min and then put into 70% ethanol and embedded in paraffin
for histological examinations. The right kidney was frozen in liquid
nitrogen and then stored at 801C.
Sirolimus levels
Sirolimus was administered daily intraperitoneally. Sirolimus levels
were measured using liquid chromatography/mass spectrometry by
the Clinical Laboratory at University Hospital. Trough levels of
sirolimus were measured just before the next dose at 16 weeks of
age. Mean levels of sirolimus (ng/ml) were 22±1 in þ /þ mice
(n¼ 3) and 20±2 in Pkd2WS25/ mice (n¼ 5).
CVD
Hematoxylin-eosin stained sections were used to determine the
CVD. This was carried out by a reviewer, blinded to the identity of
the treatment modality, using point-counting stereology.40 In
Pkd2WS25/ mice, 80% of the cysts originate from distal nephron
segments.16 At least ten areas of the medulla at 90 degrees, 180
degrees, and 270 degrees from the hilum of each section were
selected to guard against field selection variation.
Immunohistochemistry
Immunohistochemical detection of phospho-S6 ribosomal protein
(ser235/236) was carried out using a donkey-anti-rabbit antibody
(Cell Signaling Technology, Beverly, MA, USA catalog number
2211). Slides were deparaffinized and rehydrated. Antigen unmask-
ing was carried out with citrate buffer. Quenching was then
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performed using 3% hydrogen peroxide. Blocking was performed
with Tris-buffered saline and donkey serum. A donkey anti-rabbit
HRP conjugated secondary antibody was used. The sections were
incubated with DAB substrate kit for peroxidase (Vector Labs,
Burlingame, CA, USA) and visualized with hematoxylin. Negative
control sections showed no staining.
In situ detection of DNA fragmentation
The TUNEL method was used to detect in situ DNA strand breaks.
The Deadend Colorimetirc TUNEL assay kit (Promega, Madison,
WI, USA) was used. Positive and negative controls for TUNEL stain
were carried out. All cells with apoptotic morphology (cellular
rounding and shrinkage, pyknotic nuclei, and formation of
apoptotic bodies) that stained positive with the TUNEL assay were
counted.
Quantitation of tubular cell proliferation and apoptosis
The number of TUNEL positive cells per tubule was counted using a
Nikon Eclipse E400 microscope (Melville, NY, USA) equipped with
a digital camera connected to Spot Advanced imaging software
(Version 3.5) by an observer blinded to the treatment modality, as
we have previously described.1,9 Twenty areas per sample were
randomly selected at 90 degrees, 180 degrees, and 270 degrees from
the hilum of each section were selected to guard against field-
selection variation. To avoid confusion between non-cystic tubules
and small cysts, as well as potential changes in tubular cells lining
massive cysts, TUNEL-positive cells were counted in ‘medium-sized
cysts’ of approximately 250 mm diameter.
Caspase-3 assay
The activity of caspase-3 was determined by use of flourescent
substrates as we have previously described in detail.41.Whole kidney
was mixed with a lysis buffer containing 25 mM Na Hepes, 2 mM
dithiothreitol, 1 mM ethylenediaminetetraacetic acid, 0.1% 3-((3-
cholamidopropyl) dimethylammonio)-1-pro-panesulfonate, 10%
sucrose, 1 mM phenylmethylsulfonyl fluoride and 1 mM pepstatin A,
pH 7.2, and homogenized with ten strokes in a glass-Teflon
homogenizer. The lysate was then centrifuged at 41C at 100,000 g
in a Beckman (Fullerton, CA, USA) Ti70 rotor for 1 hr. The caspase
assay was performed on the resultant supernatants (cytosolic
extract). The assay buffer for caspase-3 contained 25 mM Kþ Hepes,
1 mM dithiothreitol, 0.1% 3-((3-cholamidopropyl) dimethylammo-
nio)-1-pro-panesulfonate, 50 mM KCl, pH 7.4. Ac-Asp-Glu-Val–
Asp-7-amido-4-methyl coumarin in 10% dimethyl sulfoxide was
used as a susceptible substrate for caspase-3. Peptide cleavage was
measured over 1 h at 301C using a Cytofluor 4000 series fluorescent
plate reader (Perseptive Biosystems, Framingham, MA, USA) at an
excitation wavelength of 380 nm and an emission wavelength of
460 nm. An aminomethylcoumarin standard curve was determined
for each experiment. Caspase activity was expressed in nmol
aminomethylcoumarin released per minute of incubation time per
mg of lysate protein.
Immunoblotting
Immunoblot analysis was carried out as we have previously
described.42. Whole kidney tissue was homogenized in lysis buffer
(in mM: 5 Na2HPO4, 5 NaH2PO4, 150 NaCl, 1 ethylenediaaminete-
traacetic acid, 0.1% Triton X-100, 50 NaF, 0.2 Na3VO4, and 0.1%
b-mercaptoethanol, pH 7.2) plus proteinase inhibitors: 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride, 15 mM pepstatin A, 14 mM
L-trans-epoxysuccinyl- leucylamide- (4-guanido)- butane (E-64),
40 mM bestatin, 22 mM leupeptin, and 0.8 mM aprotonin. The
homogenates were centrifuged (14,000 r.p.m at 41C for 10 min) to
remove unbroken cells and debris. Supernatants were mixed with
sample buffer containing 50 mM Tris-base (pH 6.8), 0.5% glycerol,
0.01% bromphenol blue, and 0.75% sodium dodecyl sulfate and
heated at 951C for 5 min. Equal amounts of protein (60mg/lane)
were fractionated by Tris-glycine-SDS–PAGE. The electrophoreti-
cally separated proteins were then transferred to a nitrocellulose
membrane (Millipore, Bedford, MA, USA) by wet electroblotting.
The membranes were blocked with 5% nonfat dry milk in Tris-
buffered saline tween-20 (50 mM Tris (pH 7.5), 150 mM NaCl, and
0.1% Tween buffer at pH 7.5, overnight at 41C.
Immunoblot analyses were carried out with the following
antibodies: (1) A phosho-S6 ribosomal protein (ser235/236) anti-
body (Cell Signaling Technology, Beverly, MA, USA, catalog number
2211) that detects ribosomal S6 protein only when phosphorylated
at serine 235 and 236. The main in vivo S6 ribosomal protein
phosphorylation sites for p70S6Kinase are ser235/236 and ser240/
244.43,44 Phospho-S6 ribosomal protein is recognized as a 32 kDa
protein. (2) A S6 ribosomal protein (5G10) antibody (Cell Signaling
Technology, catalog number 2217) that detects levels of total S6
protein independent of phosphorylation. Total S6 ribosomal protein
is recognized as a 32 kDa protein. (3) A goat polyclonal antibody
against Rictor (Santa Cruz biotechnology, Santa Cruz, CA, USA,
catalog number sc-50678) that recognizes a 200 kDa protein. (4) A
rabbit monoclonal antibody that detects endogenous levels of Akt
only when phosphorylated at serine 473 (Cell Signaling Technology,
catalog number 9271). Phospho-Akt (serine 4730) is recognized as a
60 kDa protein. (5) A rabbit monoclonal antibody that detects
endogenous levels of total Akt1, Akt2 and Akt 3 proteins (Cell
Signaling Technology, catalog number 9272). Total Akt is recognized
as a 60 kDa protein. (6) A rabbit monoclonal antibody to b-actin
that recognizes a 45 kDa protein (Cell Signaling Technology, catalog
number 4970).
The membranes were incubated with primary antibodies for 1 h
at room temperature, washed in Tris-buffered saline tween-20
buffer, and further incubated with donkey anti-rabbit IgG or donkey
anti-goat IgG coupled to horseradish peroxidase (Amersham,
Piscataway, NJ, USA) at 1:1000 dilution in Tris-buffered saline
tween-20 buffer for 1 h at room temperature. Subsequent detection
was carried out by enhanced chemiluminescence (Amersham),
according to the manufacturer’s instructions. Prestained protein
markers (BioRad, Hercules, CA, USA) were used for molecular mass
determination. Chemiluminescence was recorded with a film, and
results were analyzed with the 1D Image Software (Kodak Digital
Science, Rochester, NY, USA). Images for densitometry were
analyzed using 1D Image Software (Kodak digital Science).
Chemistry
BUN was measured using quantitative colorimetric urea determina-
tion (QuantiChrom urea assay kit-DIUR-500) (Bioassay Systems,
Hayward, CA, USA).
Statistical analysis
Non-normally distributed data were analyzed by the nonparametric
unpaired Mann–Whitney test. Multiple group comparisons were
carried out using two-way analysis of variance (GraphPad Prism
Version 4). A P-value of o0.05 was considered statistically
significant. Values are expressed as means±s.e.
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